<DOC>
	<DOCNO>NCT03018093</DOCNO>
	<brief_summary>The trial single arm , single-center , non-randomized phase I clinical trial design evaluate safety efficacy C-CAR011 treatment adult subject relapsed/refractory CD19+ B cell acute lymphoblastic leukemia ( r/r CD19+B-ALL )</brief_summary>
	<brief_title>A Phase I Study Evaluating Safety Efficacy C-CAR011 Treatment Adult Subjects With r/r CD19+B-ALL</brief_title>
	<detailed_description>This single-center , Open Label phase I clinical trial , 20 subject plan enrol . The trial two stage ( Phase I dose-escalation clinical trial phase I dose expansion trial ) .Subjects divide low-dose group , medium-dose group high-dose group.Additional patient enrol confirm optimal dose Dose CAR+ cells/kg Low 0.5×106 Medium 1.5×106 High 3.0×106</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<criteria>Age 1475 year old , male female . Volunteered participate study sign write informed consent form . Histologically diagnose CD19+BALL accord NCCN Acute Lymphoblastic Leukemia Clinical Practice Guidelines ( 2016 version 1 ) . Relapsed refractory CD19+BALL ( meet one follow condition ) 1 . Refractory define achieve CR ( complete remission , morphology &lt; 5 % blast ) two cycle standard chemotherapy regimen . 2 . Duration remission ≤ 12 month first induction chemotherapy regimen . 3 . Refractory disease one salvage therapy . 4 . Two Bone Marrow relapse . Morphological disease bone marrow ( ≥ 5 % blast ) . Subjects Philadelphia chromosome negative ( Ph ) disease , subject Philadelphia chromosome positive ( Ph+ ) disease intolerant fail 2 line tyrosine kinase inhibitor therapy ( TKI ) , TKI therapy contraindicate eligible . No salvage chemotherapy therapy within 4 week prior CCAR011 therapy . No immunosuppressant ( include limit systemic corticosteroid therapy ) within 4 week prior CCAR011 therapy . No antibody therapy within 4 week prior CCAR011 therapy . Normal cardiac function confirm ECHO leave ventricular ejection fraction ( LVEF ) ≧ 50 % , evidence pericardial effusion clinically significant arrhythmia . Baseline oxygen saturation ≧ 92 % room air normal pulmonary function , evidence active lung infection . No contraindication peripheral blood apheresis . Expected survival ≧ 3 month . Eastern cooperative oncology group ( ECOG ) performance status 0 1 . History severe allergic disease allergic one drug . Any kind laboratory testing : serum total bilirubin≧1.5mg/dl , serum albumin≦35g/L , ALT , AST≧2.5×ULN , serum creatinine≧2.0mg/dl , platelets≦50×109/L . Extramedullary disease . Relapsed disease allogeneic hematopoietic stem cell transplantation . Diagnosis Burkitt 's leukemia/lymphoma accord WHO classification chronic myelogenous leukemia lymphoid blast crisis . Subjects concomitant genetic syndrome Fanconi anemia , Kostmann syndrome , ShwachmanDiamond syndrome know bone marrow failure syndrome . Subjects grade III severe hypertension ( WHO/ISH Guidelines Management Hypertension , 1999 ) . History myocardial infarction , cardiac angioplasty stenting , unstable angina , clinically significant cardiac disease within 12 month prior enrollment . Subjects class III IV heart failure accord NYHA Heart Failure Classifications ; History QT prolongation clinically significant arrhythmia . History epilepsy central nervous system disorder . History presence central nervous system leukemia ( CNS3 , CNS4 ) disorder , insensitive intrathecal injection radiotherapy head/spine ; effectively control case eligible . Autoimmune diseases need treatment , immune deficiency disease need immunosuppressive therapy . Subjects TKIs therapy ( Ph+ ALL ) within 1 week prior enrollment . Severe active infection ( uncomplicated urinary tract infection , bacterial pharyngitis allow ) currently receive intravenous antibiotic therapy receive intravenous antibiotic therapy within one week . Prophylactic antibiotic , antiviral antifungal treatment permissible . Used genetically modify T cell therapy . Presence indwell line drain ( e.g. , percutaneous nephrostomy tube , indwell Foley catheter , biliary drain , pleural/peritoneal/pericardial catheter ) . Ommaya reservoirs dedicated central venous access catheter PortaCath Hickman catheter permit . Live vaccine≦4 week prior enrollment . Known infection HIV , TB , hepatitis B ( include carrier ) hepatitis C virus ( antiHCV positive ) . History alcohol addiction , drug abuse mental disease . Participated clinical trial within three month prior enrollment . Women pregnant lactate breed intent within 6 month . The investigator believe increase risk subject interference result trial .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Relapsed refractory acute lymphoblastic leukemia</keyword>
	<keyword>Anti-CD19 chimeric antigen receptor T-cell</keyword>
</DOC>